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Abstract
Background Adeno-associated virus serotype 2 (AAV2) vectors show
considerable promise for ocular gene transfer. However, one potential barrier
to efﬁcacious long-term therapy is the development of immune responses
against the vector or transgene product.
Methods We evaluated cellular and humoural responses in mice following
both single and repeated subretinal administration of AAV2, and examined
their effects on RPE65 and green ﬂuorescent protein transgene expression.
Results Following subretinal administration of vector, splenocytes and
T-cells from draining lymph nodes showed minimal activation following
stimulation by co-culture with AAV2. Neutralizing antibodies (NAbs) were
not detected in the ocular ﬂuids of any mice receiving AAV2 or in the
serum of mice receiving a lower dose. NAbs were present in the serum of
a proportion of mice receiving a higher dose of the vector. Furthermore, no
differences in immunoglobulin titre in serum or ocular ﬂuids against RPE65
protein or AAV2 capsid between treated and control mice were detected.
Histological examination showed no evidence of retinal toxicity or leukocyte
inﬁltration compared to uninjected eyes. Repeat administration of low-dose
AAV.hRPE65.hRPE65 to both eyes of RPE65−/− mice resulted in transgene
expression and functional rescue, but re-administration of high-dose AAV2
resulted in boosted NAb titres and variable transgene expression in the second
injected eye.
Conclusions These data, which were obtained in mice, suggest that,
following subretinal injection, immune responses to AAV2 are dose-
dependent. Low-dose AAV2 is well tolerated in the eye, with minimal immune
responses, and transgene expression after repeat administration of vector is
achievable. Higher doses lead to the expression of NAbs that reduce the
efﬁcacy of repeated vector administration. Copyright  2009 John Wiley &
Sons, Ltd.
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Introduction
Adeno-associated viruses (AAV) are parvoviruses that have not been asso-
ciated with any pathogenicity in humans [1]. Twelve serotypes have now
been identiﬁed [2–4] and these show tropism for many different cell
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types [2]. Studies using AAV serotype 2 (AAV2) have
demonstrated that the vector has considerable promise
for gene transfer to the liver, muscle and eye, and it has
been used to treat animal models of several inherited
conditions, such as muscular dystrophy [5], haemophilia
[6] and several types of inherited retinal degeneration
[7]. These pre-clinical studies have demonstrated that
effective treatment of these disorders might be possible
[8–10]. On the whole, however, these trials have not
demonstrated the level of efﬁcacy observed in pre-clinical
animal studies, and it appears that this might be due
to host immune responses to either the gene transfer
vector or the transgene product [11]. Because the vast
majority of the population are exposed to wild-type AAV
in the ﬁrst decade of life, patients may have pre-existing
immunity to AAV. It is estimated that up to 80% of
the population have circulating antibodies against AAV2
[12], whereas 30–50% have antibodies with neutralizing
activity [13,14]. This pre-existing immunity may inhibit
transgene expression, and any boost to an anti-vector
immune response may render future re-administration
of the vector ineffective. Another potential barrier to
efﬁcacious long-term therapy is the development of
immune responses against the transgene product.
Several detailed studies on the immune responses
occurring following AAV-mediated gene delivery in
animal models have been carried out, but have generated
some conﬂicting reports and remain inconclusive, with
immune responses appearing to depend on the route
of administration, vector dose and species differences
[15]. Immune responses against AAV vectors leading
to a reduction of transgene expression have been
observed in dogs following intramuscular administration
[16]. Here, a T-cell response against AAV2 and AAV6
vector capsid proteins was observed, regardless of the
t r a n s g e n ee x p r e s s e d ,t h em u s c l et y p ei n j e c t e do rt h e
cellular speciﬁcity of the promoter. By contrast, another
canine muscular dystrophy model showed that T-cell
inﬁltration was dependent on the transgene product;
intramuscular administration of AAV2 vectors expressing
β-galactosidase resulted in intense T-cell inﬁltration,
whereas AAV2 expressing no transgene resulted in no
cellular inﬁltration [17], despite similar doses being
used in each study. Studies in mice, however, have
demonstrated that hepatic gene transfer can achieve
transgene-speciﬁc tolerance through the induction of
regulatory T cells, even at high doses of vector [18],
whereas lower doses can result in long-term transgene
expression following intramuscular administration with
no destruction of transduced cells [19].
The high level of pre-exposure to wild-type AAV
in the human population has led to problems in
clinical trials of AAV gene transfer [11]. However,
when AAV has been administered to an immune
privileged site such as the central nervous system
(CNS), a much more limited response against the vector
has been observed systemically, with only a minority
of patients developing neutralizing antibodies (NAbs)
and no anti-vector antibodies being detected in the
CNS itself [10]. The eye is also well known to be
an immune privileged site and therefore intraocular
administration of AAV may result in a different pattern
of immune responses compared to other routes. The
mechanism of this immune privilege is multifaceted
and is the result of several mechanisms, including
physical barriers such as the blood–retinal barrier,
immunological ignorance and peripheral tolerance of eye-
derived antigens [20]. An intraocular immunosuppressive
microenvironment utilizes mechanisms such as FasL
expression on the corneal endothelium [21] and the
retinal pigment epithelium (RPE) [22] and immune
deviation in both the anterior chamber [23] and the
vitreous cavity [24]. Immune privilege might afford the
eye a level of protection, to a certain degree, against
damaging inﬂammatory responses, therefore protecting
and preserving the cells crucial to vision that are unable
to repair damage or regenerate in adult differentiated
tissue. Long-term AAV-mediated gene expression in the
mouse eye has previously been demonstrated in several
studies [25,26], suggesting that the vector is well
tolerated.
There have been extensive investigations into immune
responses against AAV following administration to the
l i v e ro rm u s c l e .B yc o n t r a s tt ot h ep r e v a l e n c eo fN A b s
in humans, the frequency of existing memory T-cells
is very low in the normal healthy population [14].
However, T-cell responses against AAV2 have been
observed transiently in a clinical trial following the
intrahepatic delivery of AAV2, where an expanded capsid-
speciﬁc CD8 + effector population was identiﬁed. This
led to the destruction of transduced hepatocytes in
one patient and a substantial increase in neutralizing
antibody levels was observed in all patients [9].
However, to date, there does not appear to have
been any detailed analysis of cellular and humoural
immune responses following intraocular administration
of AAV, and what effect these responses may have
on repeat administration of vector; this information is
critical because ocular gene therapy clinical trials are
now underway to treat Leber’s congenital amaurosis,
a form of severe early onset retinal degeneration
caused by mutations in RPE65 [27,28]. RPE65 encodes
a 65-kDa protein that is a vital component in the
visual cycle. Clinical trials have demonstrated that a
single subretinal injection of AAV2 encoding human
RPE65 can mediate a signiﬁcant improvement in visual
function, even in patients with advanced loss of vision.
One study used a hybrid constitutive cytomegalovirus
(CMV)/chicken β-actin promoter to drive the expression
of hRPE65 and administered a dose of 1.5 × 1010 vector
genomes [28]. In this trial, patients were transiently
immunosuppressed with corticosteroids and no cellular
responses against AAV2 or RPE65, or anti-RPE65
humoural responses were detected, although one patient
did show an increase in NAbs against AAV2. The other
trial administered a dose of 1 × 1011 vector genomes
of an AAV2 vector containing the endogenous hRPE65
promoter to drive hRPE65 cDNA expression [27], thereby
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restricting expression of the transgene to RPE cells
only. Patients were also transiently immunosuppressed
with corticosteroids in this trial. No cellular responses
against the AAV2 capsid were detected, and no
changes in humoural responses against RPE65 or AAV2
compared to pre-gene therapy levels were detected in
any patients. Therefore, in both studies, the vector
appears to be well tolerated in patients with missense
mutations who are transiently immunosuppressed, with
evidence of minimal inﬂammation or immune responses
against the vector or transgene product. However, it
has not yet been determined what effect previous
subretinal exposure to the AAV2 vector has on the level
of transgene expression following repeated subretinal
injection or the effect that vector re-administration has
on immune responses against the transgene product
or the vector itself, particularly in the absence of
immunosuppression. In the present study, we undertook
a thorough evaluation of the cellular and humoural
response in non-immunosuppressed mice following
administration of AAV2 encoding an endogenous retinal
protein (hRPE65) or a reporter gene encoding an
exogenous reporter (green ﬂuorescent protein, GFP),
and we examined in detail the effects of these immune
responses on transgene expression or the repeated
administration of vector.
Materials and methods
Animals
Female 4–6 weeks old C57BL/6 mice (Harlan, UK)
or rd12−/− (RPE65
−/−) mice [29] were used for all
experiments. All animals were maintained humanely with
institutional approval and in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research. At the end of the experiments, mice
were euthanased by an overdose of pentobarbital.
Viral vectors
AAV2 vectors contained either the human RPE65 cDNA
under the control of the human RPE65 promoter
(AAV.hRPE65.hRPE65), or the GFP reporter gene under
the control of the CMV intermediate-early promoter
(AAV.CMV.GFP).AllvectorscontainedtheAAV-2inverted
terminal repeats. The AAV.hRPE65.hRPE65 vector was
supplied by Targeted Genetics (Seattle, WA, USA). The
AAV.CMV.GFP was produced by transient transfection of
BHK cells with the pD10-CMV-GFP vector together with
pHAV7.3 that contains the Rep and Cap genes. HSV-DISC
w a su s e da st h eh e l p e rv i r u sa sd e s c r i b e dp r e v i o u s l y[ 3 0 ] .
Seventy-two hours post-transfection, cells were harvested
and pelleted. The pellets were freeze-thawed with
vortexing and the crude lysate was ﬁltered sequentially
through 5 µma n d0 .8 µm ﬁlters. The cleared lysate
was applied to a heparin-agarose column (Sigma, Poole,
UK) equilibrated with phosphate-buffered saline (PBS) +
2.5m MK C l+ 1m MM g C l 2 (PBS-MK). The bound virus
was washed with 10 ml of PBS-MK + 0.1M N a C l a n d
eluted with 6 ml of PBS-MK + 0.4 M NaCl. The eluate
was concentrated by spinning through Centricon-10
(Millipore, Watford, UK) columns down to a ﬁnal volume
of approximately 200–250 µl. Virus was titred by dot-
blot to determine the number of vector genomes per
millilitre by comparison to a standard curve generated by
serial dilutions of plasmid. Vector concentration was then
adjusted to 1 × 1011 or 5 × 1011 vg/ml.
Subretinal injection of viral vectors
For all experiments, mice were anaesthetized with
an intraperitoneal injection of 0.15 ml of a mixture
of Dormitor (medetomidine hydrochloride, 1 mg/ml;
Pﬁzer Pharmaceuticals, Sandwich, UK) and ketamine
(100 mg/ml; Fort Dodge Animal Health, Southampton,
UK) mixed with sterile water for injections in the
ratio 5:3:42. The pupils of all animals were dilated
using topical 1% tropicamide and 2.5% phenylepherine
(Chauvin Pharmaceuticals, Romford, UK). Viral vector
injections into the subretinal space were performed
through the peripheral cornea under the direct control of
a surgical microscope with the tip of a 10-mm 34-gauge
hypodermic needle mounted on a 5 µl syringe (Hamilton
AG, Bonaduz, Switzerland). 2 × 2 µlo fv e c t o rs u s p e n s i o n
was then injected subretinally containing 1 × 1011 or
5 × 1011 vg/ml. Anaesthesia was reversed using 0.15 ml
of Antisedan (atipamezole hydrochloride, 0.10 mg/ml;
Pﬁzer) and all animals received chloramphenicol 1% eye
ointment to the cornea.
Histological assessment of disease
Enucleated eyes were ﬁxed in 4% paraformaldehyde,
embedded in optimal cutting temperature (OCT) com-
pound (Tissue-Tek, Sakura Finetek, The Netherlands)
and cryosectioned into 8–10-µmv e r t i c a ls e r i a ls e c t i o n s
through the papillary-optic nerve axis and then stained
with haematoxylin and eosin. Sections were coded and
the number of inﬂammatory cells in the anterior and pos-
terior segments was counted. Four histological sections
per eye were evaluated. The inﬂammatory cells were
counted under ×40 magniﬁcation in ﬁve ﬁelds, each of
the anterior and posterior chambers (each ﬁeld corre-
sponds to 0.2m m 2, veriﬁed with the grid of a Neubauer
haemocytometer).
Assessment of local immune cell
priming to AAV2
Mice received subretinal injections of 2 × 2 µlo f1× 1011
or 5 × 1011 vg/ml. Seven days post-injection, mice
were euthanased and single cell suspensions were
prepared from the draining cervical lymph nodes. Cells
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were cultured in triplicate for 48 h in 96-well round
bottomed plates (2.5 × 105 c e l l s / w e l l )i nt h ep r e s e n c eo f
AAV.hRPE65.hRPE65 at two dilutions (2 × 104 and 5 ×
103 vg/ml), 2.5 µg/ml Concanavilin A (ConA) (Sigma) or
media alone. Cells were then pulsed with 0.5 µCi of [3H]-
thymidine and harvested onto glass ﬁbre mats 16 h later.
Cell proliferation was measured using a β-scintillation
counter (Perkin Elmer, Waltham, MA, USA). For analysis
by ﬂow cytometry, single cell suspensions from draining
cervical lymph nodes were incubated with antibody for
1h a 4◦C[ C D 2 5 - F I T C ,C D 4 - P E( P h a r m i n g e n ,O x f o r d ,
UK), CD69-FITC (Invitrogen, Paisley, UK)]. Cells were
then washed, ﬁxed in 4% paraformaldehyde (PFA) in PBS
and analysed on an EPICS XL ﬂow cytometer (Beckman
Coulter, High Wycombe, UK).
Assessment of systemic immune
responses to AAV22
Mice were received subretinal injections of 2 × 2 µlo f
1 × 1011 or 5 × 1011 vg/ml. Fourteen days post-injection,
mice were euthanased and single cell suspensions of
splenocytes were prepared. Cells were cultured in trip-
licate for 48 h in 96-well round bottomed plates (2.5 ×
105 cells/well) in the presence of AAV.hRPE65.hRPE65
at three dilutions (2 × 104,1× 104 and 5 × 103 vg/ml),
2.5 µg/ml ConA (Sigma) or media alone. T-cell pro-
liferation assays were performed as described above.
Supernatants from triplicate wells of cultured cells were
harvested and cytokine expression [interferon (IFN)γ and
interleukin (IL)-4] by lymphocytes in response to stimulus
wasdeterminedbyDuosetenzyme-linkedimmunosorbent
assay (ELISA) (R&D Systems, Abingdon, UK) according
to the manufacturer’s instructions.
Detection of NAbs to AAV2
Mice received subretinal injections of 2 × 2 µlo f1× 1011
or 5 × 1011 vg/ml. Three weeks post-injection, mice were
euthanased and blood was harvested by cardiac puncture
and allowed to clot on ice. Samples were then spun down
and serum stored at −80 ◦C. Ocular ﬂuids were obtained
by removal of ﬂuid from freshly enucleated eyes by
piercing the anterior chamber with a needle and drawing
ﬂuid out with a capillary tube. Fluids were stored at
−80 ◦C until use. To determine NAb titres, serial dilutions
of serum were prepared in triplicate and 1 × 108 vg of
AAV.CMV.GFP was added to each sample. Plates were
incubated at 37 ◦C for 1 h, then the contents of the wells
were added to 96-well plates of 293T cells containing
2.5 × 104 cells per well. Plates were incubated for 48 h
and then the number of GFP+ cells per well was counted
using an inverted ﬂuorescence microscope. For the ocular
ﬂuid samples, the amount of starting material was limited
and therefore all samples were diluted 1:30 in PBS before
assay. The titre of NAb was deﬁned as the highest dilution
that produced 50% ﬂuorescence compared to the media
only control.
Detection of total immunoglobulin
(Ig)A, IgG and IgM to AAV2 and
recombinant RPE65
Ocular ﬂuid and serum samples were prepared as above at
3 and 6 weeks post-subretinal injection. 96-well Maxisorp
microtitre plates (NUNC,Roskilde, Denmark)were coated
with AAV.hRPE65.hRPE65 (50000 vg/well in 100 µlo f
PBS) or recombinant human RPE65 (gift from Profes-
sor Martin Warren, University of Kent, Canterbury, UK)
(1:5000dilutionin100 µlofPBS)overnightatroomtem-
perature, then washed withPBS + 0.05%Tween-20 (PBS-
T). Plates were blocked with 1% bovine serum albumin
in PBS for ≥1 h at room temperature, then washed and
samples (1:50 or 1:100 dilution) applied. Plates were
incubated at room temperature for 1.5 h and then washed
three times with PBS-T. Bound mouse Ig was detected
with anti-mouse IgA,G,M-HRP (AdB Serotec, Kidlington,
UK) for 1.5 h at room temperature, then washed three
timeswithPBS-TandcolourwasdevelopedwithTMBsub-
strate (Pharmingen, Oxford, UK) and quenched with 1 N
HCL. Absorbance at 450 nm was quantiﬁed using a plate
reader (E Max, Molecular Devices, Wokingham, UK).
Electroretinography
Six-week-old rd12−/− mice (RPE65
−/−) received 2 × 2 µl
AAV.hRPE65.hRPE65 (1 × 1011 vg/ml) in a subretinal
injection in the right eye. Three weeks later the
left eye also received 2 × 2 µl AAV.hRPE65.hRPE65
(1 × 1011 vg/ml) via subretinal injection. Six and 9 weeks
after the ﬁrst injection, scotopic electroretinograms
(ERGs) were performed. ERGs from injected animals
were recorded in a standardized fashion, as previously
described [25]. Animals were dark-adapted overnight
and Ganzfeld ERGs were obtained simultaneously
from both eyes to provide an internal control. Mice
were anaesthetized and dilated as described above. A
single drop of 2% hydroxypropylmethylcellulose was
placed on each cornea to keep it moistened. ERGs
were recorded using commercially available equipment
(Toennies Multiliner Vision; Jaeger/Toennies, Germany)
after corneal contact electrodes and midline subdermal
reference and ground electrodes were placed. Single
ﬂash recordings were obtained at light intensities
increasing from 0.1–3000 mcds/m
2. Ten responses per
intensity level were averaged with an interstimulus
i n t e r v a lo f5 s( 0 . 1 ,1 ,1 0a n d1 0 0 m c d s / m
2)o rﬁ v e
responses per intensity with a 17-s interval (1000 and
3000 mcds/m
2).
In vivo GFP expression
Mice received a subretinal injection in the right eye of
2 × 2 µlo f5× 1011 vg/ml AAV.CMV.GFP. Three weeks
later, they received a subretinal injection in the left eye
of 2 × 2 µlo f5× 1011 vg/ml AAV.CMV.GFP. Five weeks
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after the second injection, the mice were culled and eyes
enucleated and ﬁxed in 4% PFA. Eyes were embedded in
OCT and 8–10-µm cryosections were cut. Sections were
counterstained with propidium iodide and imaged using
Q-capture Pro software (Q-Imaging, St Helens, UK).
Statistical analysis
A comparison between group ELISAs and T-cell prolif-
erations was performed using two-tailed t-tests. A com-
parison between b-wave amplitudes for ERG data was
performed using two-tailed paired t-test. In both cases,
p < 0.05 was considered statistically signiﬁcant.
Results
No early local inﬂammatory response
following subretinal administration of
AAV2
To determine whether a local cellular immune response
was initiated to AAV2 capsid proteins following subretinal
injection, C57Bl/6 mice (n = 6 per group) received a
subretinal injection of either 2 × 2 µlo f1 × 1011 or
5 × 1011 vg/ml of an AAV2 vector carrying the human
RPE65 cDNA driven by a human RPE65 promoter [27]
(AAV.hRPE65.hRPE65). A control group consisted of
uninjected C57Bl/6 mice. All animals were na¨ ive to AAV
before the experiment. Lymphocyte suspensions were
prepared from the cervical lymph nodes 7 days after
subretinal administration. Because transgene expression
is undetectable at 1 week post-injection, any immune
responses detected should be against the vector itself.
Cells from the draining lymph nodes were then
analysed to detect AAV-speciﬁc T-cells. Lymphocytes were
rechallenged in vitrowithAAV.hRPE65.hRPE65and[3H]-
thymidine-incorporation assays indicated that there was
no signiﬁcant proliferation of T-cells from injected mice
in response to co-culture with any of the dilutions of
AAV.hRPE65.hRPE65 compared to the negative media-
only control (p > 0.05) (Figure 1a). Also, there was
no signiﬁcant difference in proliferation between cells
from treated and uninjected control mice (p > 0.05).
Lymphocytes treated with ConA served as a positive
control for the T-cell proliferation assay, in which all
samples demonstrated counts per minute of >25000
(data not shown).
Flow cytometry analysis was performed to detect any
upregulation of CD25 or CD69 on CD4+ T-cells from the
draining lymph nodes of injected versus control mice. The
IL-2 receptor-α chain, CD25, is known to be expressed
on regulatory T-cells. We have studied CD25 expression
here as an activation marker because this molecule
is not expressed on na¨ ive unstimulated T-cells, but is
upregulated on na¨ ive lymphocytes following stimulation
[31–33], whereas the early membrane receptor CD69
is expressed following lymphocyte activation but is not
detected on resting lymphocytes [34,35]. An increase
in these markers would suggest that the cells were
responding to antigen. Cells from injected mice showed
no difference in the expression levels of CD25 or CD69
on CD4+ T-cells compared to cells from control mice,
indicating that the cells are not activated following co-
culture with AAV2 (Figure 1b).
Eyes were taken from all mice and haematoxylin and
eosin stained histological sections were examined for any
cellular inﬁltrate around the injection site. There was no
gross evidence of inﬁltrating cells (data not shown).
No early systemic immune responses
following subretinal administration of
AAV2
To investigate whether subretinal delivery induced a sys-
temic immune response against AAV2 capsid, C57Bl/6
mice (n = 6 per group) received either 2 × 2 µlo f
1 × 1011 or 5 × 1011 vg/ml AAV.hRPE65.hRPE65 into the
subretinal space. A control group consisted of uninjected
C57Bl/6 mice. All animals were na¨ ive to AAV before
the experiment. Because transgene expression is neg-
ligible at 2 weeks post-injection, we were looking for
immune responses only against the vector itself. Fourteen
days after subretinal injection, single cell suspensions
of splenocytes were analysed to detect AAV2-speciﬁc T-
cells. Splenocytes were rechallenged in vitro with AAV2
and proliferation assays were performed. No signiﬁcant
increase in proliferation of T-cells from injected mice
with either dose of AAV.hRPE65.hRPE65 were detected
inresponsetoco-culturewithAAV2comparedtothenega-
tivemedia-onlycontrol(p > 0.05)(Figure 2a).Also,there
was no signiﬁcant difference in proliferation between
cells from treated and uninjected control mice (p > 0.05).
ConA-treated splenocytes were used as a positive control,
in which all samples demonstrated counts per minute of
>25000 (data not shown), showing that the cells were
functional.
Supernatants from the splenocytes cultured with
AAV.hRPE65.hRPE65 were also analysed for production
of Th1( I F N γ)o rT h2 (IL-4) cytokines. No signiﬁcant
differences in the concentration of either cytokine were
detected in the culture medium following incubation
with AAV2 compared to media-only negative controls
(p > 0.05). Also, there was no signiﬁcant difference in
IFNγ (p > 0.05) (Figure 2b) or IL-4 (data not shown)
expression in T-cells taken from either injected mice
or uninjected controls, indicating that the splenocytes
were not responding to AAV2. The supernatant from
ConA-treated splenocytes was used as a positive control
in which all samples demonstrated IFNγ secretion of
>3750 pg/ml (data not shown), showing that the cells
were functional.
Histological sections from the eyes from all mice were
also analysed for any cellular inﬁltrate. There was no
gross evidence of inﬁltrating cells (data not shown).
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(a)
(b)
Figure 1. Local immune responsesof cells from draining lymph nodes7 days aftersubretinaladministrationof AAV.hRPE65.hRPE65.
(a) Cells from low-dose (2 × 2 µlo f1 × 1011 vg/ml) and high-dose (2 × 2 µlo f5 × 1011 vg/ml) AAV-injected mice or na¨ ive
uninjected controls were assayed for proliferation following incubation with 5000 or 20000 vg/ml AAV.hRPE65.hRPE65. Negative
control wells contained cells incubated in media alone. All wells were incubated for 48 h and then pulsed with [3H]-thymidine for
16 h, then harvested. All test wells co-cultured with AAV.hRPE65.hRPE65 showed no signiﬁcant increase in proliferation compared
to media-only controls (p > 0.05), and comparable responses to AAV.hRPE65.hRPE65 were observed between the injected and
uninjected control groups (p > 0.05). White bars, media-only control; black bars, 5000 vg/ml; grey bars, 20000 vg/ml. Positive
control wells were stimulated with ConA and showed cpm of >25000, indicating that the cells were functional (data not shown).
Results are expressed as the mean ± SEM cpm. (b) Lymph node cells from low-dose (2 × 2 µlo f1× 1011 vg/ml) and high-dose
(2 × 2 µlo f5 × 1011 vg/ml) AAV-injected mice or na¨ ive controls were incubated with AAV.hRPE65.hRPE65 for 48 h and then
stained for the presence of the surface bound T-cell activation markers CD25 or CD69 together with CD4. No upregulation of
activation markers was detectable on cells from injected mice compared to na¨ ive controls
No humoural responses (IgA, IgG or
IgM) against human RPE65 or AAV2
following subretinal delivery of
AAV.hRPE65.hRPE65
To investigate whether subretinal delivery induced a
humoural immune response against AAV2 capsid or
hRPE65, C57Bl/6 mice (n = 6 per group) received a
subretinal injection of either 2 × 2 µlo f1× 1011 or 5 ×
1011 vg/ml AAV.hRPE65.hRPE65. A group of uninjected
mice served as controls. The total serum IgA, IgG and
IgM against AAV2 or hRPE65 at 3 weeks post-injection
was then determined by ELISA. Equivalent cohorts of
mice were also examined at 6 weeks post-injection. No
signiﬁcant difference in circulating antibody levels was
detected between the groups of mice receiving the two
different doses of vector (p > 0.05), and treated mice
showed no signiﬁcant difference compared to uninjected
control animals for either AAV2 or hRPE65 antibodies at
either time point (p > 0.05) (Figure 3a), suggesting that
there was no increase in circulating antibodies against
either vector or transgene.
Ocular ﬂuid samples were also harvested to detect local
levels of antibody at the site of transgene expression
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(a)
(b)
Figure 2. Systemic immune responses from splenocytes 14 days
after subretinal vector administration of AAV.hRPE65.hRPE65.
(a) Splenocytes from mice injected with low-dose (2 × 2 µl
of 1 × 1011 vg/ml) and high-dose (2 × 2 µlo f5 × 1011 vg/ml)
vector and na¨ ive controls were tested for proliferation following
co-culture with dilutions (5000, 10000 or 20000 vg/ml) of
AAV.hRPE65.hRPE65. Negative control wells contained cells
incubated in media alone. Cells were incubated for 48 h
and then pulsed with [3H]-thymidine for 16 h and harvested.
All test wells incubated with AAV.hRPE65.hRPE65 showed no
signiﬁcant increase in proliferation compared to unstimulated
controls (p > 0.05), and no signiﬁcant difference was observed
between the proliferation of injected and uninjected control
groups (p > 0.05). White bars, media-only control; black bars,
5000 vg/ml; light grey bars, 10000 vg/ml; dark grey bars,
20000 vg/ml. Positive control wells were stimulated with ConA
a n ds h o w e dac p mo f>25000, indicating that cells were
functional (data not shown). Results are expressed as the
mean ± SEM cpm. (b) IFNγ expression of splenocytes following
co-incubation with AAV.hRPE65.hRPE65. Splenocytes from mice
injected subretinally with low-dose (2 × 2 µlo f1× 1011 vg/ml)
or high-dose (2 × 2 µlo f5 × 1011 vg/ml) vector or na¨ ive
uninjected controls were assayed for IFNγ expression following
co-culture with dilutions (5000, 10000 or 20000 vg/ml) of
AAV.hRPE65.hRPE65. Negative control wells contained cells
incubated in media alone. Cells were incubated for 48 h and then
supernatants were harvested and assayed by ELISA. There was
no signiﬁcant difference in IFNγ expressionby T-cells taken from
either injected mice or uninjected controls (p > 0.05), indicating
that the splenocytes were not responding to AAV2. White bars,
media-only control; black bars, 5000 vg/ml; light grey bars,
10000 vg/ml; dark grey bars, 20000 vg/ml. The supernatant
from ConA-treated splenocytes was used as a positive control
in the ELISA in which all samples demonstrated IFNγ secretion
of >3750 pg/ml (data not shown). Results are expressed as the
mean ± SEM
and were analysed by ELISA for IgA, IgG and IgM
against AAV2 or hRPE65 at 3 and 6 weeks post-injection.
Again, no signiﬁcant difference in antibody levels against
AAV2 or hRPE65 was detectable compared to controls at
either time point (p > 0.05) (Figure 3b). This experiment
was performed in mice that express endogenous RPE65.
Although our vector encodes the human form of the
protein, RPE65 is very highly conserved across species,
with 95% homology between the human and murine
forms [36], reducing the likelihood of being recognized
as nonself in wild-type mice. We also tested whether
a humoural response to hRPE65 would occur following
administration of vector to rd12−/− animals, which lack
endogenous expression of the RPE65 protein. Rd12−/−
mice (n = 6) received subretinal injections of 2 × 2 µl
of 1 × 1011 vg/ml AAV.hRPE65.hRPE65 in the right eye
and 21 days later in the left eye. Serum samples were
harvested on days 0, 21, 42 and 63 and total IgA, IgG
and IgM was assayed by ELISA. No signiﬁcant increase in
serum Ig speciﬁc for hRPE65 was detected compared to
the pre-injection baseline (p > 0.05) (Figure 3c).
Limited presence of NAbs to AAV2
following single subretinal
administration in C57Bl/6 mice
One of the major barriers to successful AAV-mediated
gene therapy is the presence of NAbs, which bind to the
vector particles, inhibiting vector uptake into the cell and
which also prevent effective re-administration of vector.
We therefore tested for the presence of NAbs against
AAV2 capsid proteins in the serum and ocular ﬂuids from
injected C57Bl/6 mice. AAV.CMV.GFP was pre-incubated
with neat and serial dilutions of serum harvested 3 weeks
aftersubretinalinjectionofAAV.hRPE65.hRPE65fromthe
mice described in the group above, or at a 1:30 dilution
of the ocular ﬂuids (as the volume of ﬂuid obtained
was a limiting factor) and then applied to 293T cells.
After 48 h, the number of GFP+ cells was quantiﬁed and
compared with control wells that received AAV.CMV.GFP
but no serum or ocular ﬂuids. We did not detect any
signiﬁcant decrease (p > 0.05) in GFP+ cells compared
to control wells, and thus no increase in NAb titre in the
mice from the uninjected group or the group receiving
the 2 × 2 µlo f1 × 1011 vg/ml dose (Figure 4a). In the
group of mice receiving the 2 × 2 µlo f5 × 1011 vg/ml
dose of virus, there was a signiﬁcant decrease in the
number of green cells in the neat serum sample compared
to the media control (p = 0.003) and also a signiﬁcant
decrease compared to neat serum from uninjected mice
(p = 0.0007). In the high-dose group, ﬁve out of six
mice showed the presence of NAbs (Figure 4a). For three
of these ﬁve mice, the NAb titre (50% inhibition) was
1:50 dilution and, for two of the mice, the NAb titre
was 1:75. This suggests that the development of NAbs
against AAV2 may be dependent on the dose of injected
vector.
No NAbs were detected in wells incubated with the
ocular ﬂuids from any of the injected mice at either dose
compared to the ocular ﬂuids from uninjected controls
or media-only wells (p > 0.05) (Figure 4b). Importantly,
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(a) (b)
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Figure 3. Total IgA, IgG and IgM in C57Bl/6 (wt) and rd12−/− (RPE65−/−) mice that received subretinal administration of
AAV.hRPE65.hRPE65 (2 × 2 µlo f1 × 1011 or 5 × 1011 vg/ml) and uninjected controls. Serum (a) and ocular ﬂuids (b) from
C57Bl/6 mice were harvested 3 or 6 weeks following vector administration and were assayed by ELISA for antibodies against AAV2
capsid and hRPE65 protein. No signiﬁcant difference in the total immunoglobulin level to AAV2 capsid or hRPE65 in serum or
ocular ﬂuids was observed between the mice that received vector and the uninjected control group at either time point (p > 0.05).
White bars, uninjected control mice; black bars, mice injected with 2 × 2 µlo f1× 1011 vg/ml; grey bars, mice injected with 2 × 2 µl
of 5 × 1011 vg/ml. (c) AAV.hRPE65.hRPE65 was injected subretinally into rd12−/− mice (2 × 2 µlo f1× 1011 vg/ml in right eye on
day 0 and in left eye on day 21). Serum was harvested at days 0, 21, 42 and 63 and assayed by ELISA for antibodies against AAV2
capsid or hRPE65. No signiﬁcant change in antibody level to AAV2 vector (p > 0.05) or hRPE65 protein (p > 0.05) was detected
following the ﬁrst or repeated subretinal administration. White bars, day 0; black bars, day 21; light grey bars, day 42; dark grey
bars, day 63. Results are expressed as the mean ± SEM OD450
eventhemice thathaddetectable circulating NAbsagainst
AAV2 in their serum showed no evidence of NAbs within
the eye.
Histological sections from eyes of all mice were also
analysed for any cellular inﬁltrate. There was no gross
evidence of inﬁltrating cells was detected (data not
shown).
Repeated subretinal administration of
low-dose AAV in vivo results in
functional rescue
For the treatment of some ocular disorders, it might
be necessary to deliver an AAV2 vector on more than
one occasion, particularly when it is necessary to treat
both eyes. In mice, AAV-mediated gene replacement
therapy for RPE65 defects has been previously shown
to restore function following subretinal administration
[37]. To determine whether administration of vector
in the second eye might be as effective as the ﬁrst
injection, 6-week-old rd12−/− mice (n = 6) received
subretinal administration of 2 × 2 µlo f1 × 1011 vg/ml
AAV.hRPE65.hRPE65 in the right eye and, 3 weeks later,
an equivalent injection in the left eye. Scotopic ERGs
were performed 6 and 9 weeks after the initial injection.
The mean b-wave amplitudes of both treated eyes were
increased 6 weeks following vector delivery compared
to untreated rd12−/− mice (data not shown), and also
continued to increase signiﬁcantly by 9 weeks post-
injection (p = 0.006, right eye, 6 weeks versus 9 weeks;
p = 0.04, left eye, 6 weeks versus 9 weeks), indicating
that the vector from the second injection was not
neutralized, resulting in hRPE65 expression in both eyes
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Figure 4. Neutralizing antibody titres in mice 3 weeks after subretinal administration of low-dose (2 × 2 µlo f1 × 1011 vg/ml)
or high-dose (2 × 2 µlo f5× 1011 vg/ml) AAV.hRPE65.hRPE65. The neutralizing antibody titre in (a) serum and (b) ocular ﬂuids
was determined by the ability to inhibit the infection of 293T cells with AAV.CMV.GFP. Each line represents a separate mouse.
There was no signiﬁcant decrease (p > 0.05) in GFP+ cells following incubation with serum from mice in the uninjected group or
mice receiving the lower dose of AAV.hRPE65.hRPE65 compared to no sera control wells, and thus no NAbs were detected. In the
group of mice receiving the higher dose of virus, there was a signiﬁcant decrease in the number of green cells in the neat serum
sample compared to the no sera control (p = 0.003) and also a signiﬁcant decrease compared to neat serum from uninjected mice
(p = 0.0007). NAbs were present ﬁve out of six mice receiving the high dose of AAV.hRPE65.hRPE65; for three of these ﬁve mice,
the NAb titre (50% inhibition) was 1:50 dilution and, for two of the mice, the NAb titre was 1:75. No NAbs were detected in the
ocular ﬂuids of any injected or na¨ ive uninjected control mice
(Figure 5). There was no signiﬁcant difference in b-wave
amplitude between the right and left eyes at either day
42 post-injection (p = 0.27) or day 63 post-injection
(p = 0.25).
Figure 5. Electroretinography of mice injected with low-dose
AAV2. Six-week-old rd12−/− (RPE65−/−)m i c ew e r ei n j e c t e d
with 2 × 2 µlo f1 × 1011 vg/ml AAV.hRPE65.hRPE65 in the
right eye and then, 3 weeks later, 2 × 2 µlo f1 × 1011 vg/ml
AAV.hRPE65.hRPE65 was administered into the left eye.
Six weeks after the initial injection, scotopic ERG showed
that b-wave amplitudes increased in both eyes compared
to uninjected controls (data not shown). Nine weeks after
subretinal injection, b-wave amplitudes continued to increase
signiﬁcantly ( : p = 0.006, right eye, 6 versus 9 weeks; :
p = 0.04, left eye, 6 versus 9 weeks), demonstrating rescue in
b o t he y e s ,w h i c hi n d i c a t e dt h a tv e ctor from the second injection
was not neutralized and that hRPE65 was expressed in both
eyes. There was no signiﬁcant difference in b-wave amplitude
between the right and left eyes at either day 42 post-injection
( : p = 0.27) or day 63 post-injection ( : p = 0.25)
Repeated delivery of high-dose AAV
in vivo results in high transgene
expression at the ﬁrst injection site but
variable expression at the second site
of vector administration
T h ep r e s e n c eo fN A b sh a sb e e ns h o w nt op r e v e n t
repeated administration of AAV2 vectors via certain
routesofdelivery. Todeterminewhethersuccessfulrepeat
administration of high-dose AAV2 was possible, a dose
that can induce the production of NAbs, 2 × 2 µlo f
5 × 1011 vg/ml AAV.CMV.GFP, was administered into the
subretinalspaceoftherighteyeofwild-typeC57Bl/6mice
(n = 8). Three weeks later, 2 × 2 µlo f5 × 1011 vg/ml
AAV.CMV.GFP was administered into the subretinal space
of the left eye. Five weeks after the second administration,
the eyes were enucleated and sectioned. There was no
evidence of gross inﬁltration of leukocytes in any eyes.
High levels of transgene expression were observed in all
the eyes that had received the ﬁrst injection (Figures 6a
and 6b). However, expression of GFP was variable in the
eyes that received the second injection. Three out of eight
mice had as many GFP+ cells in the second injected eye
as the eye that received the ﬁrst injection (Figure 6c),
whereas ﬁve out of eight had much lower numbers of
GFP+ cells in thesecond injected eye (Figure 6d).Analysis
of serum from the mice in this cohort that received
repeated administration of high-dose vector showed high
NAb titres of between 1:2000–1:5000 (data not shown)
compared toNAb titres ofupto1:75 inthe mice receiving
the single injection of high-dose vector (Figure 4a). There
did not, however, appear to be a correlation between the
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Figure 6. Fluorescence microscopy of GFP expression following re-administration of high-dose AAV2. AAV.CMV.GFP (2 × 2 µl
of 5 × 1011 vg/ml) was administered subretinally in to the right eye of C57Bl/6 mice (n = 8). Three weeks later, 2 × 2 µlo f
5 × 1011 vg/ml AAV.CMV.GFP was injected subretinally into the left eye of the same group of mice. Five weeks after the second
injection, mice were culled and eyes cryosectioned and counterstained with propidium iodide. (a, b) GFP expression was detected
in all right eyes 8 weeks after the ﬁrst subretinal injection. Five weeks after the second subretinal injection into the left eye, GFP
expression in the eye that received the second injection was variable. Three out of eight mice had as many GFP+ cells in the second
injected eye as the eye that received the ﬁrst injection (c), and the remaining mice had much lower levels of transduced cells in the
second injected eye (d), demonstrating that repeat administration of vector and transgene expression is achievable in a proportion
of eyes. Representative images are shown
NAb titre and the level of GFP expression in the second
injected eye (i.e. the animals with the lowest NAb titres
did not have the highest GFP expression). These data
suggest that the subretinal delivery of high doses of AAV2
induces the production of NAbs, with the second injection
boosting titres that may inhibit transgene expression from
subsequent administrations of AAV2 at a distant site.
Discussion
Inthepresentstudy,weinvestigatedtheimmuneresponse
to AAV2 vectors following subretinal delivery in immuno-
competent mice. The main aim of the study was to
evaluatethehumouralandcellular responses tothevector
or transgene after vector administration and to determine
whether this impacted on repeated vector delivery. To our
knowledge, this is the ﬁrst study to investigate both cel-
lular and humoural responses following AAV2 delivered
to the subretinal space. We show functional rescue of the
ERG in the rd12−/− mouse with AAV2.hRPE65.hRPE65
was observed following injection of vector into both eyes
3 weeks apart. This demonstrates that the principle that
vector of the same serotype and expressing the same
transgene can be re-administered effectively.
Over recent years, immune responses against gene
delivery vectors have become one of the most important
issues in the ﬁeld of gene therapy. It has been established
previously that,althoughadenoviral vectors induce strong
immune responses that severely inhibit the efﬁcacy of
repeated vector administration,AAV vectors are much less
immunogenic [38]. However, more recent studies have
shown that AAV is capable of stimulating an immune
response that can be detrimental to gene delivery [9,16],
although the route of administration and vector dose
appear to be key elements in determining the degree of
anti-AAV immunity that is generated.
Our data show that subretinal administration of a
lower dose (2 × 2 µlo f1 × 1011 vg/ml) AAV2 elicits
minimal immune responses. NAbs were only detected
in the serum of mice receiving the higher dose (2 × 2 µl
of 5 × 1011 vg/ml) of AAV but not at the lower dose,
suggesting that the development of NAbs are dependent
on the dose of vector, which is in agreement with other
studies [19,39]. Furthermore, no NAbs were detected
in the ocular ﬂuids of mice receiving the higher dose.
Importantly, no cellular inﬁltrate was observed in any
eyes following AAV injection, even in those mice with
circulating NAbs. This is in agreement with previous
studies investigating ocular gene delivery [40], but
contrasts with other routes of administration such as
intramuscular [16] and portal vein injection [41]. Other
studies, however, show that inﬂammation is not due the
AAV vector, but rather is dependent on the transgene
[17,42].
By contrast to the low-dose re-administration, when a
higher dose of vector was injected into the right and then
the left eye 3 weeks apart, boosted NAb titres inhibited
the transgene expression in a proportion of the eyes that
received the second injection. The transgene expression
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from the eye that had received the ﬁrst injection remained
high in all animals. This suggests that the dose of vector
delivered is a critical factor in the development of anti-
vector immune responses, which has a substantial impact
of the efﬁcacy of subsequent administration of vector. The
source of the variation in transgene expression remains
to be established. This has important implications for the
development of clinical gene delivery protocols.
In the future, it may be advantageous to engineer
vectors that lack immunogenic motifs. The heparin
sulphate proteoglycan (HSPG) motif on the VP3 capsid
protein of AAV2 has been shown to be responsible for
uptake into dendritic cells, leading to the activation of
capsid speciﬁc CTLs. When this sequence was mutated
to ablate HSPG binding, the immune response was
attenuated, yet the tropism of the vector was unchanged.
Furthermore, AAV serotypes that do not express HSPG
binding motifs appeared inherently less immunogenic
[43]. Other studies have shown that a non-HSPG-binding
mutant of AAV2 showed detargeting from the spleen
and liver compared to wild-type AAV2, leading to higher
levels of the non-HSPG-binding AAV2 mutant remaining
circulating in the blood following intravenous injection
[44].
Several studies have shown that NAbs against AAV2
do not exhibit cross reactivity against other serotypes,
allowing the possibility of re-administration with other
AAV serotypes; this ‘cross-administration’ approach has
shown efﬁcacy following intramuscular gene delivery
[15,19]. Several different AAV serotypes are able to
transduce the retina, so it may be possible to utilize
this approach for effective re-administration in the eye.
Greater immune responses have been observed in large
animal models than in mice that have received the
equivalent vector dose. Dogs appear to be particularly
susceptible, but transient immunosuppression has been
used to reduce immune responses, permitting long-term
transgene expression [45,46].
In conclusion, our data show that subretinal delivery
of AAV2 in mice is well tolerated, even in the absence of
immunosuppression. No cellular immune response was
observed to the vector in any mice. Mice receiving
the lower dose did not develop NAbs, whereas a
proportion of the mice receiving the single high-dose
of vector developed NAbs, and those receiving repeated
administration of high-dose vector all developed the
highest titres of NAbs, suggesting that the induction of
NAbs is dependent on: (i) the initial dose of vector and
(ii) NAb titres are boosted by repeat exposure to vector.
Crucially, in the present study, we showed that lower
doses vector could be re-administered and that repeat
injections of vector were successful and demonstrated
therapeutic efﬁcacy. This is important because, if both
eyes of a patient are to receive gene therapy, they are
unlikely to be injected at the same time. Therefore,
the demonstration that the same type of vector can be
administered subretinally at a later time-point is vital
to the development of a protocol requiring a second
administration of vector. Although the data obtained in
the present study suggest that immunosuppression may
not be necessary for lower vector doses, it may allow
increased doses of vector to be delivered and thus reduce
the risk of immune responses still further.
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